Sanofi (SNY) Competitors $48.88 -0.43 (-0.86%) Closing price 03:32 PM EasternExtended Trading$48.78 -0.10 (-0.21%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNY vs. NVO, NVS, AZN, GSK, TAK, ARGX, ONC, BNTX, TEVA, and SMMTShould you be buying Sanofi stock or one of its competitors? The main competitors of Sanofi include Novo Nordisk A/S (NVO), Novartis (NVS), AstraZeneca (AZN), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry. Sanofi vs. Its Competitors Novo Nordisk A/S Novartis AstraZeneca GSK Takeda Pharmaceutical argenex BeOne Medicines BioNTech Teva Pharmaceutical Industries Summit Therapeutics Sanofi (NASDAQ:SNY) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings. Is SNY or NVO more profitable? Novo Nordisk A/S has a net margin of 34.52% compared to Sanofi's net margin of 14.56%. Novo Nordisk A/S's return on equity of 80.94% beat Sanofi's return on equity.Company Net Margins Return on Equity Return on Assets Sanofi14.56% 17.15% 9.80% Novo Nordisk A/S 34.52%80.94%24.23% Do analysts rate SNY or NVO? Sanofi presently has a consensus price target of $61.50, indicating a potential upside of 25.81%. Novo Nordisk A/S has a consensus price target of $112.00, indicating a potential upside of 62.20%. Given Novo Nordisk A/S's higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Sanofi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanofi 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.11Novo Nordisk A/S 2 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.27 Does the media favor SNY or NVO? In the previous week, Novo Nordisk A/S had 11 more articles in the media than Sanofi. MarketBeat recorded 32 mentions for Novo Nordisk A/S and 21 mentions for Sanofi. Novo Nordisk A/S's average media sentiment score of 1.09 beat Sanofi's score of 0.65 indicating that Novo Nordisk A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 6 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Novo Nordisk A/S 25 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is SNY or NVO a better dividend stock? Sanofi pays an annual dividend of $1.59 per share and has a dividend yield of 3.3%. Novo Nordisk A/S pays an annual dividend of $1.63 per share and has a dividend yield of 2.4%. Sanofi pays out 56.8% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 48.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Which has more risk and volatility, SNY or NVO? Sanofi has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Which has preferable valuation and earnings, SNY or NVO? Novo Nordisk A/S has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSanofi$45.17B2.65$6.02B$2.8017.46Novo Nordisk A/S$303.14B1.02$14.64B$3.3820.43 Do insiders and institutionals hold more shares of SNY or NVO? 14.0% of Sanofi shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryNovo Nordisk A/S beats Sanofi on 12 of the 19 factors compared between the two stocks. Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNY vs. The Competition Export to ExcelMetricSanofiLarge Cap Pharma IndustryMedical SectorNASDAQ ExchangeMarket Cap$120.93B$251.97B$5.49B$9.01BDividend Yield3.26%2.85%5.39%4.09%P/E Ratio17.4627.6227.4320.06Price / Sales2.654.40398.25108.31Price / Cash9.2013.8636.1356.90Price / Book1.4717.618.085.67Net Income$6.02B$8.49B$3.16B$248.47M7 Day Performance1.06%0.50%2.12%2.90%1 Month Performance-0.62%2.17%4.43%5.75%1 Year Performance0.05%-2.31%35.62%21.36% Sanofi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNYSanofi4.3781 of 5 stars$48.89-0.9%$61.50+25.8%+1.6%$120.93B$45.17B17.4682,878Analyst ForecastNVONovo Nordisk A/S4.7541 of 5 stars$69.06+0.8%$112.00+62.2%-51.2%$308.35B$42.12B20.4377,349Positive NewsNVSNovartis1.6794 of 5 stars$121.08+0.9%$123.38+1.9%+16.3%$255.77B$53.22B18.9275,883AZNAstraZeneca2.3381 of 5 stars$69.87+0.0%$85.00+21.7%-7.6%$216.69B$54.07B28.0694,300Positive NewsGSKGSK2.1523 of 5 stars$38.38-0.5%$37.38-2.6%+0.8%$78.58B$31.53B19.7890,100Options VolumeTAKTakeda Pharmaceutical1.4845 of 5 stars$15.46+2.4%N/A+18.5%$49.19B$30.09B70.2847,300ARGXargenex4.3217 of 5 stars$551.22-1.6%$729.93+32.4%+25.2%$33.66B$2.58B34.00650Analyst ForecastHigh Trading VolumeONCBeOne Medicines3.5878 of 5 stars$242.07+0.4%$320.67+32.5%N/A$26.53B$3.81B-65.079,000BNTXBioNTech2.5644 of 5 stars$106.47-0.2%$137.86+29.5%+37.5%$25.59B$2.98B-31.313,080TEVATeva Pharmaceutical Industries4.2172 of 5 stars$16.76flat$24.13+43.9%+3.0%$19.22B$16.54B-14.5736,830SMMTSummit Therapeutics2.6908 of 5 stars$21.28+3.3%$35.09+64.9%+200.0%$15.80B$700K-62.59110Trending NewsAnalyst ForecastOptions VolumeTrading Halted Related Companies and Tools Related Companies NVO Alternatives NVS Alternatives AZN Alternatives GSK Alternatives TAK Alternatives ARGX Alternatives ONC Alternatives BNTX Alternatives TEVA Alternatives SMMT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNY) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanofi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.